Work

Supplementary Figure 4 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy

Year: 2026

Type: supplementary-materials

Abstract: Figure S4. NFAT-EGFP reporter activation in Jurkat T cells exposed to phorbol myristateacetate (PMA) and ionomycin or co-cultured with target cells expressing the cognate tumor associated antigen.

DOI: 10.1158/0008-5472.32707326

Authors: Rogelio A. Hernández-López, Tapio Kesti, Anna R. Mäkelä, Zhe Zhao, Wei Yu, Yurie Tonai, Hector J. Monzo, Kerttu Kalander, Sirpa Leppä, Päivi M. Ojala, Wendell A. Lim, Kalle Saksela

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7165036338

Cites:

Cited by:

Related to: 10